Table 2.

The impact of clinical features on the rate of ticagrelor metabolism according to linear regression analyses for each variable.

	Regression coefficient	95% confidence interval	p value	R2
Age (per year)	0.02	−0.17; 0.21	0.84	0.02
Female	0.04	−1.97; 2.05	0.97	<0.001
BMI (per kg/m2)	−0.37	−0.81; 0.06	0.09	0.16
Obesity (BMI ≥ 30 kg/m2)	−1.33	−3.49; 0.83	0.22	0.01
Creatinine at admission (per mg/dL)	−3.83	−14.08; 6.42	0.46	0.07
GFR at admission (per mL/minute)	0.05	−0.07; 0.17	0.42	0.07
STEMI	−3.67	−5.51; −1.83	0.0001	0.12
Integral ticagrelor tablets (vs. crushed ticagrelor tablets)	−2.05	−4.19; 0.09	0.06	0.03
Morphine administration	−3.04	−5.04; −0.98	0.004	0.07
History of CAD	0.39	−1.70; 2.49	0.71	0.001
Nonhemorrhagic stroke	0.10	−3.50; 3.69	0.96	<0.001
LVEF at discharge < 50%	−1.22	−3.12; 0.68	0.21	0.01
Hypertension	0.55	−1.43; 2.54	0.58	<0.01
Diabetes mellitus	−2.32	−4.62; −0.03	0.048	0.03
Dyslipidemia	−0.17	−3.22; 2.88	0.91	<0.001
Current smoker	0.63	−1.36; 2.62	0.53	<0.01

BMI: body mass index, CAD: coronary artery disease, GFR: glomerular filtration rate, LVEF: left ventricle ejection fraction, STEMI: ST-elevation myocardial infarction.